I recommend filtering him. He has done nothing but bang on about the same thing on a daily basis, repeating over and over using different wording apart from his "news is due" comments. The poster is so unbelievably transparent as a ramping member of this thread that others are either filtering or ignoring.
Anyway, back on Sareum. It looks like the SP might be rising steadily since Christmas, spike not included. I'll be happy for it to rise slowly back to .90 on or before the update RNS next month.
Please inform me of this exciting stuff about to rear its head. If CHK-1 was so fantastic, why hasnt Pfizer bought it out? I am obvioussly way out of the loop on this clearly you know everything about it. I wish hopkirk didnt block you he is clearly a lot more knowledgable than me on the subject and that being the reason you ignore his questions!
About 80% of drugs don't make it through clinical trials. Sareum has a limited pipeline of drugs and a couple of years of work left to complete. They have funds until early 2015 (1-year) but expect further fundraising would be needed 'once formal application for approval for Phase 1 clinical trials [of CHK1] is scheduled'. At a share price of 0.5p and with one (and possibly two) fundraisings expected within the next year or so -- considerable dilution can be expected. The share price has also not responded favorably to positive news in recent months. Overall, taking a 3+ year view the upside is potentially good, but for current investors this could be dead money for the next year at least. all imho.
You keep mentioning that news is due. Which you have said over and over and OVER again. I have a question for you. How do you KNOW it is due? I can post a 100 times a day saying its due. Sure as eggs are eggs news will come. Thanks for your input but maybe its time to fork off! Its nice to be positive but its obvious to long termers you are here on behalf of someone else. If you was ballanced in your views i would consider actually asking you questions to learn more. As far as i know with no figures released from china that means no upfront payment. Until news comes thats exactly what it is. You also keep saying we are way undervalued. How is Sar undervalued with no income? Thanks. Rich
So the chances of something starting phase 1 actually making it to approval is less than 10% according to this and just about everything else I've seen. Most also say oncology have higher failure rates just because of what the drugs have to do. I can't find the link but I also read that in general one third pass phase 1 and this is by far the hardest stage to overcome. Some of the failures will not have had the involvement of such high calibre partners, but some (if not most) will have had the backing of big pharma. Each one will have had expectations of success, else why pay for the trials in the first place? It's just the nature of the game. You kiss enough frogs, you will find a prince. Big pharma start loads of trials. Most fail but sometimes it makes it and when it does, the rewards more than cover the cost of all of the failures. That's why drugs cost so much.
I would agree that anything positive said about either toxicology study could see us back over 1p if it is really good but it will probably drift back a bit when people realise when trials wil start and how long they will take. Just my opinion and nearly always wrong when guessing the price :)
If and when trials start, any good news could see it really take off. And at any point a deal could be announced. But the longer we wait for that, the higher the price. Barring any bad news of course.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.